PMV Pharma

PMV Pharmaceuticals develops small molecules intended to restore the function of mutant p53. Its lead candidate, rezatapopt (PC14586), is an oral p53 reactivator designed to stabilise the p53 Y220C mutant, which the company says accounts for 1.8% of p53 mutations and occurs in at least 30 tumour types. It is being evaluated tumour-agnostically in the pivotal Phase 2 portion of the PYNNACLE Phase 1/2 study (NCT04585750), alone and with pembrolizumab, and the FDA has granted it Fast Track designation. An investigator-initiated Phase 1b study with azacitidine in TP53 Y220C relapsed or refractory AML and MDS is run by M.D. Anderson Cancer Center (NCT06616636). The company was founded in 2013 by David Mack, Arnold Levine and Thomas Shenk, and trades on Nasdaq under PMVP according to its SEC filings.